| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.68▲ | 7.68▲ | 7.68▲ | 7.59▲ | 8.23▼ |
| MA10 | 7.62▲ | 7.58▲ | 7.58▲ | 7.77▼ | 7.98▼ |
| MA20 | 7.56▲ | 7.57▲ | 7.57▲ | 8.11▼ | 6.69▲ |
| MA50 | 7.65▲ | 7.77▼ | 7.71▲ | 7.96▼ | 14.73▼ |
| MA100 | 7.77▼ | 8.03▼ | 8.22▼ | 6.89▲ | 15.96▼ |
| MA200 | 8.17▼ | 8.34▼ | 8.11▼ | 15.23▼ | 43.56▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.030▲ | 0.034▲ | 0.036▲ | -0.087▼ | 0.643▲ |
| RSI | 55.074▲ | 51.906▲ | 51.475▲ | 46.709▼ | 41.935▼ |
| STOCH | 69.940 | 68.528 | 68.528 | 36.970 | 60.794 |
| WILL %R | -15.000▲ | -15.000▲ | -15.000▲ | -64.975 | -41.729 |
| CCI | 93.614 | 93.378 | 95.938 | -43.330 | 19.235 |
|
Friday, August 15, 2025 05:40 AM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral ...
|
|
Friday, August 15, 2025 05:35 AM
Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to ...
|
|
Wednesday, August 13, 2025 05:41 AM
Aligos Therapeutics (ALGS) announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 7.69 | 7.84 | 7.42 | 7.70 | 54,558 |
| 14/08/25 | 7.35 | 7.85 | 7.35 | 7.585 | 37,088 |
| 13/08/25 | 7.57 | 7.765 | 7.3049 | 7.65 | 58,784 |
| 12/08/25 | 7.67 | 7.97 | 7.435 | 7.435 | 56,664 |
| 11/08/25 | 7.69 | 7.9738 | 7.295 | 7.57 | 51,106 |
| 08/08/25 | 8.20 | 8.49 | 7.54 | 7.69 | 84,998 |
| 07/08/25 | 7.73 | 8.24 | 7.09 | 8.13 | 114,374 |
| 06/08/25 | 8.00 | 8.42 | 7.57 | 8.04 | 60,046 |
| 05/08/25 | 7.45 | 8.2215 | 7.45 | 7.91 | 47,797 |
| 04/08/25 | 7.59 | 8.00 | 7.42 | 8.00 | 28,840 |
|
|
||||
|
|
||||
|
|